216 related articles for article (PubMed ID: 24792505)
1. Genetic factors associated with pharmacotherapy and background sensitivity to postoperative and chemotherapy-induced nausea and vomiting.
Janicki PK; Sugino S
Exp Brain Res; 2014 Aug; 232(8):2613-25. PubMed ID: 24792505
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of Postoperative Nausea and Vomiting.
Aroke EN; Hicks TL
J Perianesth Nurs; 2019 Dec; 34(6):1088-1105. PubMed ID: 31227296
[TBL] [Abstract][Full Text] [Related]
3. Is there an association between PONV and chemotherapy-induced nausea and vomiting?
Oddby-Muhrbeck E; Öbrink E; Eksborg S; Rotstein S; Lönnqvist PA
Acta Anaesthesiol Scand; 2013 Jul; 57(6):749-53. PubMed ID: 23281590
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of 5HT3-receptor antagonists in postoperative nausea and vomiting: the role of pharmacogenetics.
Theodosopoulou P; Rekatsina M; Staikou C
Minerva Anestesiol; 2023 Jun; 89(6):565-576. PubMed ID: 36852569
[TBL] [Abstract][Full Text] [Related]
5. Prevention and treatment of postoperative nausea and vomiting.
Kovac AL
Drugs; 2000 Feb; 59(2):213-43. PubMed ID: 10730546
[TBL] [Abstract][Full Text] [Related]
6. Is there a place for genetics in the management of PONV?
Candiotti K; Shrestha C; Silva Ceschim MR
Best Pract Res Clin Anaesthesiol; 2020 Dec; 34(4):713-720. PubMed ID: 33288121
[TBL] [Abstract][Full Text] [Related]
7. Exploring the multifactorial nature of postoperative nausea and vomiting in women following surgery for breast cancer.
Wesmiller SW; Sereika SM; Bender CM; Bovbjerg D; Ahrendt G; Bonaventura M; Conley YP
Auton Neurosci; 2017 Jan; 202():102-107. PubMed ID: 27729204
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genetic factors associated with nausea and vomiting in cancer patients receiving opioids.
Laugsand EA; Fladvad T; Skorpen F; Maltoni M; Kaasa S; Fayers P; Klepstad P
Eur J Cancer; 2011 Jul; 47(11):1682-91. PubMed ID: 21570824
[TBL] [Abstract][Full Text] [Related]
9. Do variations in the 5-HT3A and 5-HT3B serotonin receptor genes (HTR3A and HTR3B) influence the occurrence of postoperative vomiting?
Rueffert H; Thieme V; Wallenborn J; Lemnitz N; Bergmann A; Rudlof K; Wehner M; Olthoff D; Kaisers UX
Anesth Analg; 2009 Nov; 109(5):1442-7. PubMed ID: 19713259
[TBL] [Abstract][Full Text] [Related]
10. 5-HT3 receptor antagonists vs traditional agents for the prophylaxis of postoperative nausea and vomiting.
Loewen PS; Marra CA; Zed PJ
Can J Anaesth; 2000 Oct; 47(10):1008-18. PubMed ID: 11032279
[TBL] [Abstract][Full Text] [Related]
11. A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting.
Singh KP; Dhruva AA; Flowers E; Kober KM; Miaskowski C
Crit Rev Oncol Hematol; 2018 Jan; 121():51-61. PubMed ID: 29279099
[TBL] [Abstract][Full Text] [Related]
12. Droperidol and 5-HT3-receptor antagonists, alone or in combination, for prophylaxis of postoperative nausea and vomiting. A meta-analysis of randomised controlled trials.
Eberhart LH; Morin AM; Bothner U; Georgieff M
Acta Anaesthesiol Scand; 2000 Nov; 44(10):1252-7. PubMed ID: 11065206
[TBL] [Abstract][Full Text] [Related]
13. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
Hsu ES
Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
[TBL] [Abstract][Full Text] [Related]
14. Genetic Factors Associated with Postoperative Nausea and Vomiting: a Systematic Review.
López-Morales P; Flores-Funes D; Sánchez-Migallón EG; Lirón-Ruiz RJ; Aguayo-Albasini JL
J Gastrointest Surg; 2018 Sep; 22(9):1645-1651. PubMed ID: 29725907
[TBL] [Abstract][Full Text] [Related]
15. A history of severe nausea and vomiting during pregnancy predicts a higher incidence of postoperative nausea and vomiting after breast cancer surgery without breast reconstruction.
Wang B; Yan T; Sun L; Zhang G; Zheng H
Breast Cancer; 2021 Mar; 28(2):506-512. PubMed ID: 33242108
[TBL] [Abstract][Full Text] [Related]
16. The association of CYP2D6 genotype and postoperative nausea and vomiting in orthopedic trauma patients.
Wesmiller SW; Henker RA; Sereika SM; Donovan HS; Meng L; Gruen GS; Tarkin IS; Conley YP
Biol Res Nurs; 2013 Oct; 15(4):382-9. PubMed ID: 22718526
[TBL] [Abstract][Full Text] [Related]
17. Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
Perwitasari DA; Wessels JA; van der Straaten RJ; Baak-Pablo RF; Mustofa M; Hakimi M; Nortier JW; Gelderblom H; Guchelaar HJ
Jpn J Clin Oncol; 2011 Oct; 41(10):1168-76. PubMed ID: 21840870
[TBL] [Abstract][Full Text] [Related]
18. Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy.
Yokoi M; Tsuji D; Suzuki K; Kawasaki Y; Nakao M; Ayuhara H; Kogure Y; Shibata K; Hayashi T; Hirai K; Inoue K; Hama T; Takeda K; Nishio M; Itoh K
Support Care Cancer; 2018 May; 26(5):1505-1513. PubMed ID: 29177570
[TBL] [Abstract][Full Text] [Related]
19. CYP2D6 basic genotyping as a potential tool to improve the antiemetic efficacy of ondansetron in prophylaxis of postoperative nausea and vomiting.
Niewiński PA; Wojciechowski R; Śliwiński M; Hurkacz ME; Głowacka K; Orzechowska-Juzwenko K; Wiela-Hojeńska AK
Adv Clin Exp Med; 2018 Nov; 27(11):1499-1503. PubMed ID: 30058787
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of chemotherapy-induced nausea and vomiting.
Sugino S; Janicki PK
Pharmacogenomics; 2015 Jan; 16(2):149-60. PubMed ID: 25616101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
